Interleukin-32 contributes to invasion and metastasis of primary lung adenocarcinoma via NF-kappaB induced matrix metalloproteinases 2 and 9 expression

Cytokine

Volumn 65, Issue 1, 2014, Pages 24-32

  Zeng, Qingli ^a   Li, Shaoli ^a   Zhou, Yanbin ^a   Ou, Weijun ^a   Cai, Xingdong ^a   Zhang, Longjuan ^a   Huang, Wanling ^a   Huang, Lixia ^a   Wang, Qinqin ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

IL 32; Lung adenocarcinoma; Matrix metalloproteinase; Metastasis; NF B

Indexed keywords

GELATINASE A; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 32;

ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISTANT METASTASIS; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LUNG ADENOCARCINOMA; LYMPH NODE METASTASIS; MALE; METASTASIS; MOLECULAR PATHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TRANSACTIVATION; TUMOR INVASION; TUMOR MICROENVIRONMENT;

IL-32; INTERLEUKIN-32; LUNG ADENOCARCINOMA; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 2 AND 9; METASTASIS; MMP2 AND MMP9; NF-KAPPAB; NF-ΚB; NON-SMALL CELL LUNG CARCINOMA; NSCLC;

ADENOCARCINOMA; APOPTOSIS; CELL LINE, TUMOR; CELL MOVEMENT; FEMALE; HUMANS; INFLAMMATION; INTERLEUKINS; LUNG NEOPLASMS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NF-KAPPA B P50 SUBUNIT; PROGNOSIS; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR RELA;

EID: 84888202837     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2013.09.017     Document Type: Article

References (36)

1. Dahl C.A., Schall R.P., He H.L., Cairns J.S. Identification of a novel gene expressed in activated natural killer cells and T cells. J Immunol 1992, 148:597-603.
2. Kim S.H., Han S.Y., Azam T., Yoon D.Y., Dinarello C.A. Interleukin-32: a cytokine and inducer of TNFalpha. Immunity 2005, 22:131-142.
3. Netea M.G., Azam T., Lewis E.C., Joosten L.A., Wang M., Langenberg D., et al. Mycobacterium tuberculosis induces interleukin-32 production through a caspase-1/IL-18/interferon-gamma-dependent mechanism. PLoS Med 2006, 3:e277.
4. Lee S., Kim J.H., Kim H., Kang J.W., Kim S.H., Yang Y., et al. Activation of the interleukin-32 pro-inflammatory pathway in response to human papillomavirus infection and over-expression of interleukin-32 controls the expression of the human papillomavirus oncogene. Immunology 2011, 132:410-420.
5. Joosten L.A., Netea M.G., Kim S.H., Yoon D.Y., Oppers-Walgreen B., Radstake T.R., et al. IL-32, a proinflammatory cytokine in rheumatoid arthritis. Proc Natl Acad Sci USA 2006, 103:3298-3303.
6. Shioya M., Nishida A., Yagi Y., Ogawa A., Tsujikawa T., Kim-Mitsuyama S., et al. Epithelial overexpression of interleukin-32alpha in inflammatory bowel disease. Clin Exp Immunol 2007, 149:480-486.
7. Balkwill F., Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 2001, 357:539-545.
8. Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell 2010, 140:883-899.
9. Nishida A., Andoh A., Inatomi O., Fujiyama Y. Interleukin-32 expression in the pancreas. J Biol Chem 2009, 284:17868-17876.
10. Goda C., Kanaji T., Kanaji S., Tanaka G., Arima K., Ohno S., et al. Involvement of IL-32 in activation-induced cell death in T cells. Int Immunol 2006, 18:233-240.
11. Seo E.H., Kang J., Kim K.H., Cho M.C., Lee S., Kim H.J., et al. Detection of expressed IL-32 in human stomach cancer using ELISA and immunostaining. J Microbiol Biotechnol 2008, 18:1606-1612.
12. Marcondes A.M., Mhyre A.J., Stirewalt D.L., Kim S.H., Dinarello C.A., Deeg H.J. Dysregulation of IL-32 in myelodysplastic syndrome and chronic myelomonocytic leukemia modulates apoptosis and impairs NK function. Proc Natl Acad Sci U S A 2008, 105:2865-2870.
13. Kobayashi H., Lin P.C. Molecular characterization of IL-32 in human endothelial cells. Cytokine 2009, 46:351-358.
14. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
15. Molina J.R., Yang P., Cassivi S.D., Schild S.E., Adjei A.A. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008, 83:584-594.
16. Greene F.L., Page D.L., Fleming I.D., Fritz A.G., Blach C.M., Haller D.J., et al. American joint committee on cancer staging manual 2009, Springer, New York. 6th ed.
17. Li J., Zhang N., Song L.B., Liao W.T., Jiang L.L., Gong L.Y., et al. Astrocyte elevated gene-1 is a novel prognostic marker for breast cancer progression and overall patient survival. Clin Cancer Res 2008, 14:3319-3326.
18. Cheng C.Y., Kuo C.T., Lin C.C., Hsieh H.L., Yang C.M. IL-1beta induces expression of matrix metalloproteinase-9 and cell migration via a c-Src-dependent, growth factor receptor transactivation in A549 cells. Br J Pharmacol 2010, 160:1595-1610.
19. Lo F.Y., Chen H.T., Cheng H.C., Hsu H.S., Wang Y.C. Overexpression of PAFAH1B1 is associated with tumor metastasis and poor survival in non-small cell lung cancer. Lung Cancer-J Iaslc 2012, 77:585-592.
20. Dvorak H.F. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986, 315:1650-1659.
21. Mantovani A., Bussolino F., Dejana E. Cytokine regulation of endothelial cell function. Faseb J 1992, 6:2591-2599.
22. Coussens L.M., Tinkle C.L., Hanahan D., Werb Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 2000, 103:481-490.
23. Choi J.D., Bae S.Y., Hong J.W., Azam T., Dinarello C.A., Her E., et al. Identification of the most active interleukin-32 isoform. Immunology 2009, 126:535-542.
24. Kim S., Lee S., Her E., Bae S., Choi J., Hong J., et al. Proteinase 3-processed form of the recombinant IL-32 separate domain. BMB Rep 2008, 41:814-819.
25. Egberts J.H., Cloosters V., Noack A., Schniewind B., Thon L., Klose S., et al. Anti-tumor necrosis factor therapy inhibits pancreatic tumor growth and metastasis. Cancer Res 2008, 68:1443-1450.
26. Apte R.N., Dotan S., Elkabets M., White M.R., Reich E., Carmi Y., et al. The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metast Rev 2006, 25:387-408.
27. Sullivan N.J., Sasser A.K., Axel A.E., Vesuna F., Raman V., Ramirez N., et al. Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells. Oncogene 2009, 28:2940-2947.
28. Vidal-Vanaclocha F., Fantuzzi G., Mendoza L., Fuentes A.M., Anasagasti M.J., Martin J., et al. IL-18 regulates IL-1beta-dependent hepatic melanoma metastasis via vascular cell adhesion molecule-1. Proc Natl Acad Sci USA 2000, 97:734-739.
29. Sunaga N., Imai H., Shimizu K., Shames D.S., Kakegawa S., Girard L., et al. Oncogenic KRAS-induced interleukin-8 overexpression promotes cell growth and migration and contributes to aggressive phenotypes of non-small cell lung cancer. Int J Cancer 2012, 130:1733-1744.
30. Chen J.J., Yao P.L., Yuan A., Hong T.M., Shun C.T., Kuo M.L., et al. Up-regulation of tumor interleukin-8 expression by infiltrating macrophages: its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer. Clin Cancer Res 2003, 9:729-737.
31. Li W., Liu Y., Mukhtar M.M., Gong R., Pan Y., Rasool S.T., et al. Activation of interleukin-32 pro-inflammatory pathway in response to influenza A virus infection. PLoS One 2008, 3:e1985.
32. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006, 441:431-436.
33. Lu K.W., Chen J.C., Lai T.Y., Yang J.S., Weng S.W., Ma Y.S., et al. Gypenosides inhibits migration and invasion of human oral cancer SAS cells through the inhibition of matrix metalloproteinase-2-9 and urokinase-plasminogen by ERK1/2 and NF-kappa B signaling pathways. Hum Exp Toxicol 2011, 30:406-415.
34. Li J., Lau G.K., Chen L., Dong S.S., Lan H.Y., Huang X.R., et al. Interleukin 17A promotes hepatocellular carcinoma metastasis via NF-κB induced matrix metalloproteinases 2 and 9 expression. PLoS One 2011, 6:e21816.
35. Pan X., Cao H., Lu J., Shu X., Xiong X., Hong X., et al. Interleukin-32 expression induced by hepatitis B virus protein X is mediated through activation of NF-kappaB. Mol Immunol 2011, 48:1573-1577.
36. Punturieri A., Szabo E., Croxton T.L., Shapiro S.D., Dubinett S.M. Lung cancer and chronic obstructive pulmonary disease: needs and opportunities for integrated research. J Natl Cancer Inst 2009, 101:554-559.